A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Sirolimus (Primary)
- Indications Posterior uveitis
- Focus Adverse reactions
- Sponsors Santen Incorporated
- 03 Jun 2017 This trial has been completed in Austria.
- 25 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2014 New trial record